Latest long-term debt for 6492.TWO: $8.3M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Senhwa Biosciences (6492.TWO) currently reports a long-term debt of $8.3M as of June 2026. That compares with $17M in the prior-year period — down 52.0% year over year. Use the charts on this page to explore Senhwa Biosciences's long-term debt history and peer comparisons.
Senhwa Biosciences's long-term debt decreased from $17M to $8.3M — a 52.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Senhwa Biosciences reported $8.3M in long-term debt as of June 2026. That compares with $17M in the prior-year period — down 52.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current long-term debt of $8.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Senhwa Biosciences, and consider following 6492.TWO for alerts when major investors trade the stock.
Senhwa Biosciences is classified in the Healthcare sector. On long-term debt, it currently shows $8.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 6492.TWO with unrelated industries.